July 1, 2026 July 1, 202692Bio, Inc. Doses First Patient in Ph1 Trial of NTB-928 in Ovarian Cancer92Bio, Inc. a clinical-stage biotechnology company developing next-generation T-cell engaging antibodies (TCEs), today announced dosing of the first […]
November 4, 2025 November 4, 2025Discovery of a Novel CD123 x Gamma Delta T cell Engager for the Treatment of Acute Myeloid Leukemia40th Society for Immunotherapy for Cancer (SITC) | 2025
